search
Back to results

Treatment of OSA Associated Hypertension With Nebivolol or Hydrochlorothiazide (nebhctz)

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Nebivolol
Hydrochlorothiazide
Sponsored by
University of California, San Diego
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

30 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients ranging from 20 - 80 years
  • Body mass index (BMI) of 20-38 to include the typical obese OSA patients
  • Hypertension with blood pressures > 140/90 but less than 180/105 mmHg.
  • Apnea-hypopnea index above 10

Exclusion Criteria:

  • Receiving sleep medicines (including heavy alcohol use) or drugs with adverse interactions with study medication.
  • Women who have premenstrual syndrome, or those who are pregnant or capable of pregnancy and unwilling to use effective non-hormonal contraception
  • Shift workers or have symptoms of narcolepsy, restless legs syndrome or insomnia, in order to minimize confounding effects of other sleep disorders
  • Have apneas which are primarily central
  • Have sleep fragmentation caused by syndromes such as chronic pain or movement disorders
  • Have diseases such as asthma or chronic obstructive pulmonary disease that compromises respiration.
  • Have known coronary or cerebral vascular disease, history of arrhythmias, cardiomyopathy, history of psychosis, current alcohol or drug abuse.
  • Have any contraindications to any study materials, such as heart block.
  • Have secondary hypertension
  • Have creatinine levels above 2.5 mg %, more than 1+ proteinuria by dipstick, hematuria or electrolyte disorders.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Experimental

    Arm Label

    Placebo, Nebivolol, Hydrochlorothyazide

    Placebo, Hydrochlorothyazide, Nebivolol

    Arm Description

    Sequence: Placebo, Then Nebivolol 5mg for 2 weeks followed by nebivolol 10 mg for 4 weeks,Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks.

    Sequence: Placebo, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks, Then Nebivolol 5mg for 2 weeks followed by nebivolol 10 mg for 4 weeks.

    Outcomes

    Primary Outcome Measures

    24-h, Wake and Sleep Period Systolic and Diastolic Blood Pressure
    24-h Systolic Blood Pressure is the average of all 24-h Ambulatory Systolic Blood Pressure recordings. The Wake Period Systolic Blood Pressure is the average of all Systolic Blood Pressures recorded every 15 minutes during the wake period. The Sleep Period Systolic Blood pressure is the average of all Systolic Blood Pressures recorded every 30 minutes during the sleep period. 24-h Diastolic Blood Pressure is the average of all 24-h Ambulatory Diastolic Blood Pressure recordings. The Wake Period Diastolic Blood Pressure is the average of all Diastolic Blood Pressures recorded every 15 minutes during the wake period. The Sleep Period Diastolic Blood pressure is the average of all Diastolic Blood Pressures recorded every 30 minutes during the sleep period.

    Secondary Outcome Measures

    Full Information

    First Posted
    March 7, 2016
    Last Updated
    September 22, 2020
    Sponsor
    University of California, San Diego
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02710071
    Brief Title
    Treatment of OSA Associated Hypertension With Nebivolol or Hydrochlorothiazide
    Acronym
    nebhctz
    Official Title
    A Blinded Crossover Study of the 24 Hour Blood Pressure Response to Treatment of Obstructive Sleep Apnea Associated Hypertension With Nebivolol or Hydrochlorothiazide
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2020
    Overall Recruitment Status
    Completed
    Study Start Date
    January 2015 (undefined)
    Primary Completion Date
    April 2016 (Actual)
    Study Completion Date
    April 2016 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of California, San Diego

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Patients who have obstructive sleep apnea (OSA) frequently stop breathing while they sleep. They often develop high blood pressure. We are not sure what drug is best to treat the high blood pressure. This study will give the patients nebivolol or hydrochlorothiazide (HCTZ) for 6 weeks after 2 weeks of placebo. The blood pressure response will be evaluated by 24 hour monitoring.
    Detailed Description
    This is a blinded crossover study measuring the antihypertensive efficacy of nebivolol vs HCTZ in up to 34 subjects. Subjects with an apnea-hypopnea index (AHI) > 10 and hypertension can enter the study. Hypertension is defined as a systolic blood pressure (SBP) > 140 or a diastolic blood pressure (DBP) > 90 on the average of three seated blood pressure measurements or a history of medical therapy for hypertension. Subjects who have tried and abandoned continuous positive airway pressure (CPAP) therapy for sleep apnea are eligible for this study. All others will be advised that CPAP is preferred treatment for sleep apnea and are eligible only if they decline CPAP or use it for too short a time at night to be effective. Then patients will have their antihypertensive drugs tapered off and receive single blind placebo for two weeks. After that, all subjects receive nebivolol or HCTZ for six weeks with a full evaluation at that time. Subjects are crossed over to HCTZ 12.5 mg for 2 weeks followed by HCTZ 25 mg for 4 more weeks. Nebivolol 5 mg will be taken daily at bedtime for 2 weeks and then as a dose of 10 mg for the remaining 4 weeks. Subjects will receive a telephone call at the time of increased dosage as a reminder. Blood, urine and 24-hour blood pressure measurements, hemodynamic measurements, questionnaires and drug accountability are measured in the same manner toward at the the end of placebo and each drug treatment. The entire study will take 14 weeks, although each study period may be lengthened by one week if necessary for the convenience of the subject's personal schedule. Patients will provide blood pressure readings from their home monitor or in clinic and will not have the dose increased if they have systolic blood pressure below 105 mm Hg or side effects suggesting that an increased dose might worsen side effects At the end of each treatment period, subjects will undergo noninvasive hemodynamic testing. Ultrasound will be used to measure aortic diameter and blood velocity in the ascending aorta in order to better estimate cardiac output. Then, finger plethysmography will be used to acquire beat-to-beat finger blood pressure and pulse rate. Beat-to-beat derived hemodynamic variables will be calculated by a model flow algorithm (e.g. brachial artery flow, stroke volume, cardiac output, ejection time, blood pressure rate of change, peripheral resistance). Applanation tonometry will be used to obtain pulse wave velocity and central arterial pressure. ECG will be recorded with standard ECG leads to determine heart rate variability in both time and frequency domains. Spontaneous baroreflex will be determined from beat-to-beat changes in blood pressure and pulse pressure interval. Forearm reactive hyperemia will be used to quantify endothelial dysfunction during 4 minutes of post-ischemic change. Subjects will then complete an Epworth Sleepiness Scale questionnaire (ESS) and a Functional Outcomes of Sleep Questionnaire (FOSQ) to find whether they are drowsy in the daytime and if they feel that they are compromised by not having adequate rest. Any adverse event will be recorded. They are asked about any concurrent medication over the prior period, including prescription medication, over the counter medication, and caffeine intake. Medication compliance is evaluated by pill count. Those who fail to return their pill bottle are requested to bring it in. Finally, a 24-hour ambulatory blood pressure monitor (ABPM) will be attached to automatically collect blood pressure and heart rate values every 15 minutes during the wake period and every 30 minutes during the sleep period.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Crossover Assignment
    Masking
    ParticipantInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    41 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Placebo, Nebivolol, Hydrochlorothyazide
    Arm Type
    Experimental
    Arm Description
    Sequence: Placebo, Then Nebivolol 5mg for 2 weeks followed by nebivolol 10 mg for 4 weeks,Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks.
    Arm Title
    Placebo, Hydrochlorothyazide, Nebivolol
    Arm Type
    Experimental
    Arm Description
    Sequence: Placebo, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks, Then Nebivolol 5mg for 2 weeks followed by nebivolol 10 mg for 4 weeks.
    Intervention Type
    Drug
    Intervention Name(s)
    Nebivolol
    Other Intervention Name(s)
    Bystolic
    Intervention Description
    Nebivolol 5mg then nebivolol 10 mg
    Intervention Type
    Drug
    Intervention Name(s)
    Hydrochlorothiazide
    Other Intervention Name(s)
    Hydrodiuril
    Intervention Description
    Hydrochlorothiazide 12.5 mg then hydrochlorothiazide 25 mg
    Primary Outcome Measure Information:
    Title
    24-h, Wake and Sleep Period Systolic and Diastolic Blood Pressure
    Description
    24-h Systolic Blood Pressure is the average of all 24-h Ambulatory Systolic Blood Pressure recordings. The Wake Period Systolic Blood Pressure is the average of all Systolic Blood Pressures recorded every 15 minutes during the wake period. The Sleep Period Systolic Blood pressure is the average of all Systolic Blood Pressures recorded every 30 minutes during the sleep period. 24-h Diastolic Blood Pressure is the average of all 24-h Ambulatory Diastolic Blood Pressure recordings. The Wake Period Diastolic Blood Pressure is the average of all Diastolic Blood Pressures recorded every 15 minutes during the wake period. The Sleep Period Diastolic Blood pressure is the average of all Diastolic Blood Pressures recorded every 30 minutes during the sleep period.
    Time Frame
    At the end of 2 weeks of placebo therapy, at the end of 6 weeks of Nebivolol therapy and at the end of 6 weeks of hydrochlorothiazide therapy.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    30 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients ranging from 20 - 80 years Body mass index (BMI) of 20-38 to include the typical obese OSA patients Hypertension with blood pressures > 140/90 but less than 180/105 mmHg. Apnea-hypopnea index above 10 Exclusion Criteria: Receiving sleep medicines (including heavy alcohol use) or drugs with adverse interactions with study medication. Women who have premenstrual syndrome, or those who are pregnant or capable of pregnancy and unwilling to use effective non-hormonal contraception Shift workers or have symptoms of narcolepsy, restless legs syndrome or insomnia, in order to minimize confounding effects of other sleep disorders Have apneas which are primarily central Have sleep fragmentation caused by syndromes such as chronic pain or movement disorders Have diseases such as asthma or chronic obstructive pulmonary disease that compromises respiration. Have known coronary or cerebral vascular disease, history of arrhythmias, cardiomyopathy, history of psychosis, current alcohol or drug abuse. Have any contraindications to any study materials, such as heart block. Have secondary hypertension Have creatinine levels above 2.5 mg %, more than 1+ proteinuria by dipstick, hematuria or electrolyte disorders.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Michael G. Ziegler, M.D.
    Organizational Affiliation
    Professor of Medicine
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    21326007
    Citation
    Ziegler MG, Milic M, Sun P. Antihypertensive therapy for patients with obstructive sleep apnea. Curr Opin Nephrol Hypertens. 2011 Jan;20(1):50-5. doi: 10.1097/MNH.0b013e3283402eb5.
    Results Reference
    background

    Learn more about this trial

    Treatment of OSA Associated Hypertension With Nebivolol or Hydrochlorothiazide

    We'll reach out to this number within 24 hrs